浏览全部资源
扫码关注微信
1.安吉县中医医院西药房,浙江 湖州 313100
2.解放军东部战区总医院临床药学科,南京 210002
副主任药师,硕士。研究方向:群体药动学。E-mail:yhb5442387@163.com
教授,硕士生导师,博士。研究方向:群体药动学。 E-mail:ruijianzhong@126.com
纸质出版日期:2023-01-30,
收稿日期:2022-08-15,
修回日期:2022-12-10,
扫 描 看 全 文
叶红波,宋洋洋,芮建中.蒙特卡罗模拟评估肾功能不全老年患者使用美罗培南的给药方案 Δ[J].中国药房,2023,34(02):190-194.
YE Hongbo,SONG Yangyang,RUI Jianzhong.Evaluation of the dosing regimen of meropenem in elderly patients with renal insufficiency with Monte Carlo simulation[J].ZHONGGUO YAOFANG,2023,34(02):190-194.
叶红波,宋洋洋,芮建中.蒙特卡罗模拟评估肾功能不全老年患者使用美罗培南的给药方案 Δ[J].中国药房,2023,34(02):190-194. DOI: 10.6039/j.issn.1001-0408.2023.02.12.
YE Hongbo,SONG Yangyang,RUI Jianzhong.Evaluation of the dosing regimen of meropenem in elderly patients with renal insufficiency with Monte Carlo simulation[J].ZHONGGUO YAOFANG,2023,34(02):190-194. DOI: 10.6039/j.issn.1001-0408.2023.02.12.
目的
2
探讨美罗培南在肾功能不全的老年患者中合适的给药方案。
方法
2
采用美罗培南在老年患者中的二房室群体药动学参数进行蒙特卡罗模拟,模型纳入肾功能对参数的影响,设计给药剂量为0.5、1、2 g,给药方式为静脉注射(持续6 min)和静脉滴注(0.5、3 h),给药频率为q12 h、q8 h,共计18种给药方案组合,分别计算%fT
>4MIC
≥40%和
C
min
≤27.5 mg/L的达标概率,以优选给药方案。
结果
2
对于肌酐清除率(CLcr)≤40 mL/min的老年患者,最低抑菌浓度(MIC)为1 mg/L时,推荐的给药方案是“0.5 g,静脉滴注0.5 h,q12 h”“1 g,静脉注射,q12 h”;MIC为2 mg/L时,推荐的给药方案是“0.5 g,静脉注射,q8 h”“1 g,静脉滴注0.5 h,q12 h”;MIC为4、8 mg/L时,推荐的给药方案是“1 g(或2 g),静脉注射,q8 h”。对于CLcr为50 mL/min的老年患者,MIC为1 mg/L时,推荐的给药方案是“0.5 g,静脉注射,q8 h”“1 g,静脉注射,q12 h”;MIC为2、4、8 mg/L时,推荐的给药方案是“0.5 g(或1 g,或2 g),静脉滴注0.5 h,q8 h”。上述所有方案的达标概率都在96.6%及以上。“2 g,静脉注射或静脉滴注0.5 h,q8 h”的给药方案在1 000次模拟中,约有40次模拟出现
C
min
>27.5 mg/L的情况,可能出现神经系统不良反应。
结论
2
对于肾功能不全老年患者,美罗培南给药方案应以CLcr=40 mL/min为界进行相应调整,同时警惕神经系统毒性。
OBJECTIVE
2
To explore the appropriate dosing regimen of meropenem in the elderly with renal insufficiency.
METHODS
2
The meropenem population pharmacokinetics of the two-compartment model of elderly patients were applied for Monte Carlo simulation. The model included the effect of renal function on the parameters. The designed dosages were 0.5, 1, 2 g; the administration modes included intravenous injection (lasting for 6 min) and intravenous drip (0.5, 3 h); the administration frequencies were q12 h, q8 h. A total of 18 dosing regimens were designed. The probability of target attainment of %fT
>4MIC
≥40% and
C
min
≤27.5 mg/L were calculated respectively to optimize the dosing regimen.
RESULTS
2
For elderly patients with creatinine clearance (CLcr) ≤40 mL/min, when the minimum inhibitory concentration (MIC) was equaled to 1 mg/L, the suggested dosing regimens were “0.5 g, intravenous drip 0.5 h, q12 h” “1 g, intravenous injection, q12 h”. When the MIC was equaled to 2 mg/L, the suggested dosing regimens were “0.5 g, intravenous injection, q8 h” “1 g, intravenous drip 0.5 h, q12 h”. When the MIC was equaled to 4, 8 mg/L, the suggested dosing regimens were “1 g (or 2 g), intravenous injection, q8 h”. For elderly patients with CLcr equal to 50 mL/min, when the MIC was equaled to 1 mg/L, the suggested dosing regimens were “0.5 g, intravenous injection, q8 h”“1 g, intravenous injection, q12 h”. When the MIC was equal to 2, 4, 8 mg/L,the suggested dosing regimens were“0.5 g (or 1 g, or 2 g), intravenous drip for 0.5 h, q8 h”. The appropriate dosing regimens of all the above protocols were above 96.6%. In the dosing regimen of “2 g,intravenous injection or intravenous drip 0.5 h, q8 h”,
C
min
>27.5 mg/L occurred in 40 times among the 1 000 times of simulation, indicating adverse reactions of the nervous system may occur.
CONCLUSIONS
2
For the elderly patients with renal insufficiency, the dosing regimen of meropenem should be adjusted accordingly with CLcr=40 mL/min as the boundary, and the toxicity of nervous system should be considered at the same time.
美罗培南蒙特卡罗模拟二房室肾功能不全老年患者
Monte Carlo simulationtwo-compartmentrenal insufficiencyelderly patientsneurotoxicity
张晨,滕文兵,刘香芳,等. 蒙特卡罗模拟优化CRRT脓毒症患者的美罗培南给药方案[J]. 今日药学,2019,29(3):192-195.
邹雅敏,张迪,董亚琳. 美罗培南不同给药方案有效性与耐药风险的蒙特卡洛模拟[J]. 医药导报,2021,40(5):664-669.
叶龙强,徐志伟,董绉绉,等. 美罗培南对产碳青霉烯酶肠杆菌科细菌的药效学研究[J]. 中国现代应用药学,2020,37(16):1968-1972.
张芹. 应用蒙特卡罗模拟优化肺炎克雷伯菌感染时美罗培南的给药方案[J]. 现代医药卫生,2017,33(10):1586-1588.
肖永红,胡云建. 亚胺培南、美罗培南、头孢哌酮-舒巴坦和哌拉西林-他唑巴坦对医院获得革兰阴性菌感染治疗方案的蒙特卡洛模拟评估[J]. 中华内科杂志,2017,56(8):595-600.
沈惠峰,张睢扬,常艳,等. 用SAS迭代及蒙特卡罗模拟优化美罗培南的使用[J]. 中国临床药理学与治疗学,2012,17(5):529-535.
杨婷婷,姚慧,彭丽清. 重症感染患者美罗培南血药浓度与不良反应相关性研究[J]. 中国处方药,2021,19(11):91-92.
ZHOU Q T,HE B,ZHANG C,et al. Pharmacokinetics and pharmacodynamics of meropenem in elderly Chinese with lower respiratory tract infections:population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study[J]. Drugs Aging,2011,28(11):903-912.
陈婷,黄晓会,陈霁晖,等. 老年患者美罗培南血药浓度监测结果分析及药物动力学研究[J]. 中国药师,2017,20(3):402-404.
叶红波,芮建中,薛领. NONMEM法优化替考拉宁专家共识中肾功能不全时的治疗方案[J]. 中国现代应用药学,2019,36(15):1959-1962.
周庆涛,贺蓓. 美罗培南个体化给药的研究进展[J]. 中国抗生素杂志,2009,34(5):263-266,290.
洪冰,胡卢丰,章小敏,等. 美罗培南两步点滴法治疗重症监护病房严重感染的疗效分析[J]. 中国医院药学杂志,2017,37(23):2383-2386.
FOY F,LUNA G,MARTINEZ J,et al. An investigation of the stability of meropenem in elastomeric infusion devices[J]. Drug Des Devel Ther,2019,13:2655-2665.
王君耀,方滢芝,阮邹荣. 美罗培南与4种注射液配伍后的稳定性考察[J]. 中国药学杂志,2003,38(9):714-715.
李疆,仇群慧. 美罗培南与3种输液的配伍稳定性研究[J]. 中国药房,2014,25(29):2764-2766.
Chinese XDR Consensus Working Group,GUAN X,HE L,et al. Laboratory diagnosis,clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli:a Chinese consensus statement[J]. Clin Microbiol Infect,2016,22(Suppl 1):S15-S25.
0
浏览量
3
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构